HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
about
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitorsDrugging topoisomerases: lessons and challengesSynthetic lethal screens as a means to understand and treat MYC-driven cancersHER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo.Dissect the Dynamic Molecular Circuits of Cell Cycle Control through Network Evolution Model.TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinomaClonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples.Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancerDeletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.Immunohistochemistry for myc predicts survival in colorectal cancer.HER2 in solid tumors: more than 10 years under the microscope; where are we now?c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer.A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.Copy number increase of HER-2 in colorectal cancers.Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionHuman Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics.HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAFCause and consequences of genetic and epigenetic alterations in human cancer.Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis.Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer.Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.KRAS and TP53 mutations in colorectal carcinoma.Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.Genome-wide analyses of long noncoding RNA expression profiles in lung adenocarcinoma.TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.Expression of Wnt-signaling pathway genes and their associations with miRNAs in colorectal cancer.Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.
P2860
Q24595585-EC7E3A18-E0BA-4781-BCDE-78DEE26A8040Q27000099-6606735A-1141-4973-8D0D-4F7005C0E10AQ27006010-E1960322-02ED-42A7-9C77-A46076BFC27BQ27852057-E6F5AC4A-C9C4-49B9-A4BA-A3BE37B2A98EQ33404601-75C4A76E-DF6E-472F-9603-DF6EEB71940EQ33561346-BD22D1A2-B5FB-4DF7-A8C2-27DE0D1736B2Q34044864-6B6CDCFB-1520-4B5E-81BC-77BA786745E3Q34164365-9A59BE0E-439C-4053-88EC-435EBB4C1C03Q34442193-108E4D67-4FA0-4EF6-BAA8-153074DD4EE0Q35011886-2966B2BD-D070-40B7-BBC5-01196D44952FQ35087649-10B8A9DE-8F67-4CE5-AAAD-096E6DFA0BB3Q35211263-C97D654C-5ADD-4EE0-B521-1082385C0017Q35795297-AC9F1154-90ED-43A6-A425-3104F84E69BAQ35921206-C16CF66C-1597-4C36-A6DD-A252CEFE3E97Q36135873-616E8E59-FD96-441B-A8E0-68C40029C03BQ36388523-5BA2FA49-D13E-4848-9CDD-2CED743A726BQ36636356-D9741A8D-5928-4F14-8A59-36CCBC0B8081Q36655951-13D7E991-5BBF-42B7-AD34-85D916F617E2Q36728796-1B973999-CB7B-4693-B557-BB70253AC940Q37149773-B6FF584B-E31A-4AD2-8CF3-1B64DBFC9AE1Q37511752-A162C81D-C8F9-4D91-BB3A-A5A44A1A9D31Q38096413-CF6F379B-0887-4315-A5A4-426F40BE6E11Q38621219-2C4AB7CA-5048-4F2C-85C0-F0BFB334CCFAQ38648453-4ED2F7E1-DE10-4CE5-8E4A-FAE032094D6EQ38827897-A1FB2F40-3D44-4878-AE7B-64DC537838C8Q39011091-7C5CB85C-6067-4C2C-B7D6-E8D5090DD886Q39186813-8B129E81-1333-4FD9-822E-F8AD5FEC1FDCQ39612011-5FC5C716-1D75-4812-872C-2C019012CCE6Q39680556-32F2861E-D40C-4F25-8FDB-96A20EDA98D3Q42362550-E5BBB50E-1ED5-49B5-BF00-AC4ED2671005Q43635123-59683402-B4E7-4A38-AF52-D4120F202CA9Q47164589-721BA88D-F4F8-444F-A6B2-9592FAD66A31Q48845796-E60E75D9-440D-4D35-9710-F43D231698CFQ49787639-2C17AF9E-28E2-4C16-BEF9-ED0843DA9A41Q50096089-6286EF55-BCBE-4E47-848D-C339A25062A5Q51776452-5B22343C-AC6E-44B1-9710-3151A2FB9CEDQ53080639-98181BC8-C2A1-4B6F-AFB1-EE9E967A9F7CQ54469155-8263CF67-F5C9-43BE-9896-B0ABC11AA7AAQ54540314-5A10439D-B144-46FD-8D56-63E6589DEA31
P2860
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
@en
type
label
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
@en
prefLabel
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
@en
P2093
P2860
P356
P1476
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
@en
P2093
Abdul K Siraj
Adnan Ezzat
Coya Tapia
Fouad Al-Dayel
Guido Sauter
Hadeel Al-Mana
Hedvika Novotny
Khawla Al-Kuraya
Luigi Terracciano
Martina Mirlacher
P2860
P304
P356
10.1136/JCP.2006.038281
P407
P577
2006-08-01T00:00:00Z